SLS · NASDAQ
SELLAS Life Sciences Group (SLS) Stock Price & Fundamentals
SELLAS Life Sciences Group (SLS) closed at $850.79 on Oct 9, 2026, down 0.38% from the previous close of $854.04.
Share price, past year
1Y +16.60%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $850.79 |
| Sep 30, 2026 | $860.31 |
| Aug 31, 2026 | $827.84 |
| Jul 31, 2026 | $885.18 |
| Jun 30, 2026 | $850.70 |
| May 29, 2026 | $892.58 |
| Apr 30, 2026 | $841.77 |
| Mar 31, 2026 | $846.07 |
| Feb 27, 2026 | $870.39 |
| Jan 30, 2026 | $866.49 |
| Dec 31, 2025 | $801.22 |
| Nov 28, 2025 | $770.24 |
| Oct 31, 2025 | $742.68 |
Key statistics
- Market cap
- $171.79B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.21
- Revenue (TTM)
- —
- Net income (TTM)
- −$32.46M
- Shares outstanding
- 201.9M
- Dividend yield
- —
- 52-week range
- $722.97 – $899.03
SELLAS Life Sciences Group's market cap is $171.79B, based on a share price of $850.79 and 201.9M shares outstanding as of Jun 30, 2026.
Financials
SELLAS Life Sciences Group reported revenue of $0.00 for fiscal 2023, down 100.00% from fiscal 2022.
SELLAS Life Sciences Group reported a net loss of $26.86M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2023ended Dec 31, 2023 | $0.00 | −100.0% | −$37.34M | — | −$1.34 | — |
| FY2022ended Dec 31, 2022 | $1.00M | −86.8% | −$41.30M | −4,130.1% | −$2.13 | — |
| FY2021ended Dec 31, 2021 | $7.60M | +300.0% | −$20.70M | −272.4% | −$1.34 | — |
| FY2020ended Dec 31, 2020 | $1.90M | — | −$16.76M | −882.0% | −$2.11 | — |
| FY2019ended Dec 31, 2019 | $0.00 | −100.0% | −$19.29M | — | −$10.92 | — |
| FY2014ended Dec 31, 2014 | $9.32M | +274.7% | — | — | — | −$42.93M |
| FY2013ended Dec 31, 2013 | $2.49M | — | — | — | — | −$29.25M |
| FY2012ended Dec 31, 2012 | $0.00 | — | — | — | — | — |
| FY2011ended Dec 31, 2011 | $0.00 | — | — | — | — | −$14.72M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2023ended Dec 31, 2023 | $0.00 | — | — |
| Q3 FY2023ended Sep 30, 2023 | $0.00 | — | — |
| Q2 FY2023ended Jun 30, 2023 | $0.00 | — | — |
| Q1 FY2023ended Mar 31, 2023 | $0.00 | — | — |
| Q4 FY2022ended Dec 31, 2022 | $0.00 | — | — |
| Q3 FY2022ended Sep 30, 2022 | $0.00 | — | — |
| Q2 FY2022ended Jun 30, 2022 | $0.00 | — | — |
| Q1 FY2022ended Mar 31, 2022 | $1.00M | — | — |
Company profile
- Name
- SELLAS Life Sciences Group, Inc.
- Ticker
- SLS
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 7 Times Square, Suite 2503, New York, NY 10036
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001390478
Recent SEC filings
- Aug 11, 2026
- Aug 11, 2026
- Jul 27, 2026
- Jun 25, 2026
- Jun 18, 2026
- Jun 2, 2026
- May 12, 2026
- May 12, 2026
Frequently asked questions
What is SELLAS Life Sciences Group's stock price?
SELLAS Life Sciences Group (SLS) closed at $850.79 on Oct 9, 2026, down 0.38% from the previous close of $854.04.
What is SELLAS Life Sciences Group's market cap?
SELLAS Life Sciences Group's market cap is $171.79B, based on a share price of $850.79 and 201.9M shares outstanding as of Jun 30, 2026.
How much revenue does SELLAS Life Sciences Group make?
SELLAS Life Sciences Group reported revenue of $0.00 for fiscal 2023, down 100.00% from fiscal 2022.
Does SELLAS Life Sciences Group pay a dividend?
SELLAS Life Sciences Group's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from SELLAS Life Sciences Group, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures